[{"address1": "4660 La Jolla Village Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92122", "country": "United States", "phone": "650 800 3717", "website": "https://www.revbiosciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Mr. James M. Rolke", "age": 54, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 649250, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chester Stanley Zygmont III", "age": 43, "title": "CFO & Corporate Secretary", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 479141, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sandra  Vedrick", "title": "Vice President of Human Resources & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carol  Odle", "title": "Senior Director of Clinical Projects", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.73, "open": 1.72, "dayLow": 1.61, "dayHigh": 1.72, "regularMarketPreviousClose": 1.73, "regularMarketOpen": 1.72, "regularMarketDayLow": 1.61, "regularMarketDayHigh": 1.72, "beta": 0.175, "forwardPE": -0.31548756, "volume": 34047, "regularMarketVolume": 34047, "averageVolume": 83642, "averageVolume10days": 28200, "averageDailyVolume10Day": 28200, "marketCap": 2694351, "fiftyTwoWeekLow": 1.61, "fiftyTwoWeekHigh": 35.4, "fiftyDayAverage": 2.19802, "twoHundredDayAverage": 11.77566, "currency": "USD", "enterpriseValue": -8627855, "floatShares": 1627497, "sharesOutstanding": 1632940, "sharesShort": 17742, "sharesShortPriorMonth": 32814, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.0109, "heldPercentInsiders": 0.00324, "heldPercentInstitutions": 0.019809999, "shortRatio": 0.39, "shortPercentOfFloat": 0.0109, "impliedSharesOutstanding": 1632940, "bookValue": 25.13, "priceToBook": 0.06565858, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -120254, "trailingEps": -48.51, "forwardEps": -5.23, "lastSplitFactor": "1:30", "lastSplitDate": 1706140800, "enterpriseToEbitda": 1.0, "52WeekChange": -0.9460784, "SandP52WeekChange": 0.22256601, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "REVB", "underlyingSymbol": "REVB", "shortName": "Revelation Biosciences, Inc.", "longName": "Revelation Biosciences, Inc.", "firstTradeDateEpochUtc": 1605623400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f994477e-3690-3dde-965e-6f9faa0f03d6", "messageBoardId": "finmb_696222591", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.65, "targetHighPrice": 25.0, "targetLowPrice": 12.4, "targetMeanPrice": 18.7, "targetMedianPrice": 18.7, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 11991701, "totalCashPerShare": 7.344, "ebitda": -8631615, "quickRatio": 2.155, "currentRatio": 2.183, "returnOnAssets": -0.61079, "returnOnEquity": -0.031229999, "freeCashflow": -4111234, "operatingCashflow": -7286286, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-31"}]